![]() CytoDyn has taken measures to correct these problems and has put competent people in a position of oversight. Recent legal documents from the lawsuit with CytoDyn’s ex- CRO, Amarex, have unveiled that Amarex was not only inefficient, but bordering on incompetent in their filings and correspondence with the FDA. The reasons for delaying the BLA filing are coming into greater focus, and as the truth is coming out, it is becoming evident that the delay has less to do with management’s incompetence as it does with Amarex. One of the most long standing criticisms of CytoDyn’s management is their inability to correctly file their Biologic License Application (BLA) for HIV in a timely manner. There are other reasons for the waning share price. The company has still been able to attract investment and raise sufficient money to meet its burn rate with some recent fixed price offerings. These fears were unfounded because there are 800 million authorized and only 669 million outstanding leaving more than enough shares on hand for $100 million plus at a modest discount to the current market price. This delay fueled fears that the company would be unable to raise money for operations because they were out of shares. They did, however, have a pyrrhic victory that postponed the shareholder meeting to November 24th for the lack of a quorum. The 13-D Proxy group, known as “Advancing Leronlimab,” who seem to have run the disinformation campaign so they could sow doubt among investors and win a proxy contest, was handily defeated in court. Positive reports like CytoDyn’s cancer update, NASH update, or the Breakthrough Therapy Designation (BTD) application filing have gotten seemingly no traction, but things may be turning around. Investor exhaustion and capitulation is evident in the failure of great news to move the stock upwards. The 18th century saying from Baron Rothschild is to “buy when there is blood in the streets, even when it’s your own.” If you have a contrarian investment philosophy and prefer to buy stocks at rock bottom, CYDY is the ideal candidate and now is the bottom. The problem with this approach is that the low price is a result of a massive disinformation campaign that has distorted the price. Conventional wisdom not only says run from this name, but run fast. As the company pursued its EUA it seems the world was against them the FDA not only cut off their lifesaving compassionate use program but also admonished them with a precedent-setting FDA statement that inaccurately characterized their drug leronlimab. The price is under constant pressure and the assault from the short mafia has now expanded their base of influence beyond Stat News, to Fierce Biotech and the Wall Street Journal. ![]() The capitulation is evident on almost all of the social media boards as the ratio of negative to positive posts is over 10 to 1. ![]() The longs are exhausted and refuse to even try to mount a defense against the constant manipulation of facts on social media. The stock price just keeps dripping down lower and lower. They can’t even get the pandemic to cooperate as Brazil’s new infections are at record lows. In general, the forces of nature seem to be against them. ![]() CytoDyn Inc (OTCMKT: CYDY) has been under considerable selling pressure since April and nothing seems to be able to stop it. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |